Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cartesian Therapeutics, Inc. (RNAC)
Price$9.12Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $400,000 | $38.3M | $26.0M | $110.8M | $85.1M | $16.6M | $6.7M | $903,000 | $207,000 | $8.1M | $6.0M | $3.0M |
| Research & development | $58.0M | $45.1M | $71.3M | $72.4M | $68.7M | $54.5M | $42.7M | $47.7M | $45.2M | $29.7M | $23.0M | $10.5M |
| Operating expenses | $146.2M | $82.8M | $112.4M | $96.2M | $89.7M | $73.4M | $59.1M | $65.9M | $64.0M | $42.8M | $31.3M | $18.4M |
| Operating income | −$143.4M | −$43.9M | −$86.4M | $14.5M | −$4.6M | −$56.8M | −$52.5M | −$65.0M | −$63.8M | −$34.7M | −$25.3M | −$15.4M |
| Operating margin | −35,851.25% | −114.69% | −332.32% | 13.12% | −5.40% | −342.36% | −785.61% | −7,200.66% | −30,813.53% | −428.92% | −420.96% | −506.55% |
| EBITDA | −$140.2M | −$40.3M | −$84.0M | $16.6M | −$2.9M | −$55.1M | −$50.5M | −$64.0M | −$63.0M | −$33.9M | −$24.3M | −$14.5M |
| EBITDA margin | −35,056.75% | −105.19% | −322.88% | 14.96% | −3.38% | −331.95% | −755.64% | −7,089.92% | −30,451.21% | −419.00% | −403.59% | −478.13% |
| Net income | −$130.3M | −$77.4M | −$219.7M | $35.4M | −$25.7M | −$68.9M | −$55.4M | −$65.3M | −$65.3M | −$36.2M | −$25.2M | −$12.9M |
| Net profit margin | −32,575.50% | −202.28% | −844.91% | 31.94% | −30.19% | −414.99% | −828.97% | −7,235.44% | −31,556.04% | −447.98% | −418.80% | −423.68% |
| Basic EPSper basic share | -$5.02 | -$4.48 | -$49.76 | $7.21 | -$6.61 | -$20.42 | -$36.64 | -$87.69 | -$96.10 | -$116.82 | -$454.35 | -$235.44 |
| Diluted EPSper diluted share | -$5.02 | -$4.49 | -$49.76 | $3.00 | -$6.61 | -$20.42 | -$36.64 | -$87.69 | -$96.10 | -$116.82 | -$454.35 | -$235.44 |
Owners
Reported shareholders
≈32.07%of listed shares
SPRINGER TIMOTHY A9.63M shares · Jan 2, 2026
View holders
| Holder | % owned |
|---|---|
SPRINGER TIMOTHY A | ≈32.07%9.63M shares |
Kalayoglu Murat | ≈19.38%5.82M shares |
Hoge Elizabeth / Seven One Eight Three Four Irrevocable Trust | ≈19.38%5.82M shares |
Squarepoint Ops LLC | 7.51%2.25M shares |
BlackRock, Inc. | 2.73%819.24K shares |
683 Capital Management, LLC | 2.16%650K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.85%555.82K shares |
FMR LLC | 1.23%368.43K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.19%356.53K shares |
AQR CAPITAL MANAGEMENT LLC | 1.19%356.46K shares |
Brunn Carsten | ≈1.08%323.53K shares |
MILLENNIUM MANAGEMENT LLC | 1.03%309.89K shares |
TWO SIGMA INVESTMENTS, LP | 0.99%296.29K shares |
STATE STREET CORP | 0.83%249.21K shares |
MARSHALL WACE, LLP | 0.78%232.92K shares |
UBS Group AG | 0.69%208.65K shares |
Jupiter Topco LLC | 0.67%200.91K shares |
Privium Fund Management B.V. | 0.50%151.68K shares |
Davis Blaine | ≈0.40%121.22K shares |
NORTHERN TRUST CORP | 0.35%105.7K shares |
Percentages use 30.04M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 6, 2026Form 4 | Brunn CarstenPresident and CEO | SellCommon Stock | 23.8K | $6.82 | $162.1K | 323.5K |
| Jan 6, 2026Form 4 | Miljkovic MilosChief Medical Officer | SellCommon Stock | 3.6K | $6.82 | $24.4K | 58.8K |
| Jan 6, 2026Form 4 | Davis BlaineChief Financial Officer | SellCommon Stock | 10.6K | $6.82 | $72.2K | 121.2K |
| Dec 4, 2025Form 4 | BARABE TIMOTHY CDirector | BuyCommon Stock | 30.0K | $6.86 | $205.8K | 54.4K |
| Apr 11, 2025Form 4 | SPRINGER TIMOTHY ADirector,TenPercentOwner | BuyCommon Stock · indirect | 36.3K | $10.77 | $391.4K | 656.5K |